10 dec: WARRANTS OPTAGELSE TIL HANDEL MED VIRKNING FRA DEN 11.12.2018
10 dec: Jacob Friis fortsætter som cheftræner i AaB
10-12-2018 14:41:05

Grant of Restricted Stock Units to Board Members, Management and Employees and Grant of Warrants to Management and Employees in Genmab

Company Announcement

Copenhagen, Denmark; December 10, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that at a board meeting

the board

decided to grant 80,380 restricted stock units to members of the board of directors, management and employees of the company as well as the company's subsidiaries and 213,613 warrants to management and employees of the company as well as the company's subsidiaries.

Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The vesting of the restricted stock units granted to the members of management will be subject to forward looking performance criteria. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 1,025.

The restricted stock units will vest on the first banking day of the month following a period of three years from the date of grant. Furthermore, the restricted stock units are subject to vesting conditions set out in the restricted stock unit program adopted by the board of directors in accordance with the general guidelines for incentive-based remuneration adopted by the shareholders at the annual general meeting. Information concerning Genmab’s restricted stock unit program can be found on www.genmab.com under Investors > Stock information > Restricted stock units.

The exercise price for each warrant is DKK 1,025. Each warrant is awarded cost-free and entitles the owner to subscribe one share of nominally DKK 1 subject to payment of the exercise price. By application of the Black-Scholes formula, the fair value of each warrant can be calculated as DKK 366.04.

The warrants vest three years after the grant date, and all warrants expire at the seventh anniversary of the grant date. The new warrants have been granted on the terms and conditions set out in the warrant program adopted by the board of directors on March 28, 2017. Information concerning Genmab’s warrant schemes can be found on www.genmab.com under Investors > Stock information > Warrants.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications

T: +45 33 44 77 20; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Company Announcement no. 35

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Relateret indhold
19 jul - 
Fredagens aktier: Pandora fik stryg på børsen og tynged..
19 jul - 
Aktier/middag: Halter efter Europa trods plusser - især..
19 jul - 
Aktier/åbning: Ørsted dribler eliteindekset i plus
Relateret debat
04:43 - 
Hmm. Det er med blandede følelser jeg for tid til anden..
20 jul - 
Kunne det skyldes enten planer om opkøb, eller planer o..
20 jul - 
Rettede emissioner som denne er ofte omkring 5% rabat. ..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 jul
GEN
Med markering:   https://ir.genmab.com/news-releases/news-release-details/genmab-announces-net-sales..
7
04:43
GEN
Hmm. Det er med blandede følelser jeg for tid til anden følger med i Genmab trådende. Da Genmab s b..
6
16 jul
GEN
Evt godkendelse forventes ultimo 2019 og på markedet  Q1 20 SC-behandlingen bliver sandsynligvis væs..
5
16 jul
GEN
Markedsværdi ca. 75 mia for hele butikken svarer vel stort set til den pris som Celgene for ca. 2 år..
5
19 jul
GEN
Mon vi skal igennem de 1234 idag    https://www.euroinvestor.dk/nyheder/2019/07/19/genmab-barclays-s..
4
16 jul
GEN
Nogle analytikere påpeger at trækker man valuta og engangs pillerier ud, så er det som forventet, do..
4
19 jul
GEN
Genmab Announces Submission of Extension of Marketing Authorization to European Medicines Agency for..
3
16 jul
GEN
"en grådig ledelse som man tænker vil gøre alt for at øge kursen"   Den er jeg med på. 
3
16 jul
GEN
Ang. analytiker kommentarer. Jeg er kunde i Nordea og har derfor mulighed for at læse Novrods Genmab..
3
16 jul
GEN
vækst:   1. ste kvartal fra 2018 til 2019:   46 %   2. en kvartal fra 2019 til 2019:   51 %   Vækste..
3

Aktier/tendens: Ørsted tiltænkt helterolle i positiv aktieåbning

19-07-2019 08:09:28
Der er positive nyheder fra både den danske energikoncern Ørsted og biotekselskabet Genmab som oplæg til fredagens danske aktiehandel, hvor markedet før åbningen generelt er bagud i forhold til den stigning de amerikanske aktier præsterede i torsdagens handel.Sammen med stigende futures for både det amerikanske S&P 500-indeks og for det tyske DAX-indeks tidlig fredag morgen peger det mod en positi..

Danske Bank Q2: Kundeflugten fortsætter i udfordret bank

18-07-2019 11:06:22
Kunder siger fortsat farvel til Danske Bank - omend i et langsommere tempo end tidligere. I andet kvartal valgte 4300 Nemkonto-kunder at slukke for den forbindelse til banken, hvor de første seks måneder samlet gav en kundeafgang på 13.600 Nemkonto-kunder svarende til 1 pct. af bankens Nemkonto-kundebase.Det er fortsat bankens hvidvasksag i Estland, der danner ringe i vandet - men også sagen om pr..

Aktier/tendens: Storbanker i fokus efter årle morgen-regnskaber

18-07-2019 08:26:01
Det er storbankerne Nordea og Danske Bank, der tager overskrifterne på det danske aktiemarked torsdag morgen og lægger retningen for børsens C25-indeks, der samtidig vil være presset af internationale kursfald.I USA lukkede Wall Street med fald i størrelsesordenen 0,4-0,7 pct., og i futuresmarkedet er faldene blevet uddybet med yderligere 0,3-0,5 pct.I Asien har investorernes mangel på begejstring..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Genmab A/S 1,219.50 -0,6% Fald i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. juli 2019 09:05:38
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190703.1 - EUROWEB1 - 2019-07-21 09:05:38 - 2019-07-21 09:05:38 - 1 - Website: OKAY